Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
March 14, 2023 17:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting TherapyALLO-316...
March 02, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
March 01, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy

Publication Reviews Investigation of a Chromosomal Rearrangement Observed in a Single Patient Receiving Gene-Edited Allogeneic CAR T Treatment for Large B Cell LymphomaCase Reveals Normal T Cell...
February 28, 2023 16:02 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Initiated Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory (R/R) Large B Cell Lymphoma (LBCL)Presented Data Highlighting Industry-Leading Allogeneic...
February 21, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...
February 01, 2023 14:55 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
January 25, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

Preclinical Efficacy and Safety Results Indicate AlloCAR T™ Development Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue Toxicity SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE...
January 24, 2023 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
January 17, 2023 16:05 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...